Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial
Journal of Antimicrobial Chemotherapy · 03.10.2025 · 80 (10) · 2719-2726
DOI: 10.1093/jac/dkaf278 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 12.08.2025. Verfasst von Jinhee Jo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. Hauptthemen laut MEDLINE: Feces, Bile Acids and Salts, Tetracyclines, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Paratek Pharmaceuticals, Inc.
Abstract (Originalsprache)
Background
There is an urgent need to develop new antimicrobials effective intravenously for Clostridioides difficile infection (CDI). Omadacycline is an aminomethylcycline tetracycline available orally and intravenously with potent in vitro activity against C. difficile and a low propensity to cause CDI. The purpose of this study was to assess the safety, faecal pharmacokinetics, microbiome and bile acid changes in healthy subjects given a course of intravenous omadacycline with oral omadacycline step down after 5 days.
Methods
This Phase 1, open-label study was conducted in healthy volunteers 18–40 years. Subjects received a 5-day course of omadacycline given intravenously followed by 5 days of oral omadacycline. Stool samples were analysed for omadacycline concentrations, gut microbiome changes and bile acid changes from baseline.
Results
Eight healthy volunteers aged 30 ± 4 years (50% Female) were recruited and all completed therapy. All subjects had detectable omadacycline stool concentrations after 48 hours of intravenous dosing and averaged 195 ± 97 µg/g (mean ± SD) by day 5. Omadacycline concentrations increased rapidly after the start of oral therapy on day 6 with average concentrations of 854 ± 404 µg/g of stool by day 10. Microbiome and bile acid evaluations showed preservation of key microbiome taxa that confer health benefit and preservation of bile acid homeostasis.
Conclusion
Intravenous omadacycline followed by oral step-down administration in healthy adults achieved high faecal concentrations while preserving key bacterial species and bile acid homeostasis in the gut. These findings support Phase 2 studies directed towards the development of omadacycline as a CDI-targeted antibiotic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
- Division of Pharmacotherapy and Translational Sciences, The University of Texas at Austin College of Pharmacy, San Antonio, TX, USA.
- Pharmacotherapy Education and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
- Department of Pharmacotherapy and Pharmacy Services, University Hospital, San Antonio, TX, USA.
- Department of Internal Medicine, Section of Infectious Diseases, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
- Department of Pathology and Immunology, Baylor College of Medicine; Houston, TX, USA.
ORCID-Profile: Kevin W Garey
Förderung
- NIH HHS
- NIAID NIH HHS
- Paratek Pharmaceuticals, Inc
- University of Houston New Investigator Award
- NIH NIAID
- National Institute Allergy and Infectious diseases
- National Institutes of Health
Zitieren
APA
Jo, J., Carlson, T. J., Hu, C., Williamson, J. C., Belin, Y. T., Horvath, T. D., Haidacher, S. J., Bassères, E., Begum, K., Alam, M. J., & Garey, K. W. (2025). Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. Journal of Antimicrobial Chemotherapy, 80(10), 2719-2726. https://doi.org/10.1093/jac/dkaf278
Vancouver
Jo J, Carlson TJ, Hu C, Williamson JC, Belin YT, Horvath TD, et al. Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial. Journal of Antimicrobial Chemotherapy. 2025;80(10):2719-2726. doi:10.1093/jac/dkaf278
BibTeX
@article{Jo2025,
author = {Jo, Jinhee and Carlson, Travis J and Hu, Chenlin and Williamson, John C and Belin, Yolanda T and Horvath, Thomas D and Haidacher, Sigmund J and Bassères, Eugénie and Begum, Khurshida and Alam, M Jahangir and Garey, Kevin W},
title = {Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {10},
pages = {2719--2726},
doi = {10.1093/jac/dkaf278}
}
EUVIMED